Annexon Biosciences
Biotechnology ResearchView the employees at
Annexon Biosciences-
Joseph Vereen Neuromuscular Research | Pathobiology | Digital Pathology
-
United States
-
Top 10%
Logan Kuhn Research Intern at Annexon Biosciences-
San Francisco, California, United States
-
Rising Star
Chuck Bradley Clinical Development and Clinical Operations Consultant-
Half Moon Bay, California, United States
-
Top 10%
Qing Chang M.D., Ph.D. Vice President, Global Team Leader, Portfolio Strategy and Management at Annexon Biosciences-
San Francisco Bay Area
-
Rising Star
Overview
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
-